• Explore /
  • Poster
  • / Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).

Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

David Spigel

David R. Spigel

Sarah Cannon Research Institute, Nashville, TN

David R. Spigel , Jamie E. Chaft , Scott N. Gettinger , Bo H. Chao , Luc Yves Dirix , Peter Schmid , Laura Quan Man Chow , Colombe Chappey , Marcin Kowanetz , Alan Sandler , Roel Peter Funke , Naiyer A. Rizvi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01846416

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8028)

DOI

10.1200/jco.2015.33.15_suppl.8028

Abstract #

8028

Poster Bd #

350

Abstract Disclosures

Similar Posters

First Author: Vassiliki Papadimitrakopoulou

First Author: Makoto Nishio

First Author: Li Zhang

First Author: Rita Migliorino